News
In the near term, commercial efforts might raise the chances that new patients are prescribed Novo Nordisk’s drug, assuming ...
Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.
Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...
The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...
Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...
A study of two blockbuster weight-loss drugs showed that users of Eli Lilly’s Zepbound lost just over 2 inches more off their ...
Novo Nordisk (NVO, Financials) shares fell nearly 4% after the company said CEO Lars Fruergaard Jrgensen will step down. A ...
Discover why Novo Nordisk A/S' undervalued shares present a buying opportunity, with strong sales growth, profitability, and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback